ROCKVILLE, MD, June 2, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to rhCC10 (recombinant human Club Cell 10 kDa Protein), the company’s lead product candidate, for the prevention of bronchopulmonary dysplasia and chronic respiratory morbidity (CRM) in preterm infants.

For more information, click here.